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Disruption of STAT3 signalling promotes
KRAS-induced lung tumorigenesis
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STAT3 is considered to play an oncogenic role in several malignancies including lung cancer;
consequently, targeting STAT3 is currently proposed as therapeutic intervention. Here we
demonstrate that STAT3 plays an unexpected tumour-suppressive role in KRAS mutant lung
adenocarcinoma (AC). Indeed, lung tissue-specific inactivation of Stat3 in mice results in
increased KrasG12D-driven AC initiation and malignant progression leading to markedly
reduced survival. Knockdown of STAT3 in xenografted human AC cells increases tumour
growth. Clinically, low STAT3 expression levels correlate with poor survival and advanced
malignancy in human lung AC patients with smoking history, which are prone to KRAS
mutations. Consistently, KRAS mutant lung tumours exhibit reduced STAT3 levels.
Mechanistically, we demonstrate that STAT3 controls NF-kB-induced IL-8 expression by
sequestering NF-kB within the cytoplasm, thereby inhibiting IL-8-mediated myeloid tumour
infiltration and tumour vascularization and hence tumour progression. These results elucidate
a novel STAT3–NF-kB–IL-8 axis in KRAS mutant AC with therapeutic and prognostic
relevance.
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L
ung cancer is still the leading cause of cancer deaths
worldwide1. The most frequent genetic alterations found in
lung adenocarcinomas (ACs) are missense mutations and
amplifications of kirsten rat sarcoma viral oncogene (KRAS) and
epidermal growth factor receptor (EGFR) in about 30% and 20%
of all Caucasian cases, respectively2,3. Although several targeted
anti-EGFR therapies are effective in patients with EGFR
mutations, oncogenic KRAS is still considered as an
undruggable target. To elucidate further treatment strategies,
the focus has therefore shifted towards KRAS-cooperating and
downstream signalling pathways. Signal transducer and activator
of transcription 3 (STAT3) represents one important
transcription factor thought to cooperate with rat sarcoma viral
oncogene (RAS) mutations during tumorigenesis4,5. STAT3 is
activated in response to several cytokines and growth factors,
such as interleukin-6 (IL-6), oncostatin-M (OSM) and epidermal
growth factor (EGF). Upon binding of the ligand to its cognate
receptor, STAT3 becomes tyrosine-phosphorylated and forms
homodimers or heterodimers before translocating into the
nucleus to induce the transcription of several target genes
implicated in cell cycle regulation, apoptosis, angiogenesis,
tumour invasion and metastasis6. Depending on the oncogenic
driver mutation or on the cell type, STAT3 has been reported to
play either pro-oncogenic4,5,7 or tumour-suppressive roles in vivo
and in vitro8–12. Interestingly, STAT3 was shown to be activated
in 54% of lung AC patient samples and human lung cancer cell
lines13–15. Furthermore, based on in vitro and xenograft models,
STAT3 is thought to play a tumour-promoting role in non-small-
cell lung cancer (NSCLC) and during acquired drug
resistance13,14,16–18.
Here, we investigated the role of STAT3 during oncogenic
Kras-driven lung tumorigenesis using the Cre-inducible Lox-
Stop-Lox-KrasG12D/þ knock-in lung cancer mouse model19 and
a human xenograft model. Surprisingly, our results show that
STAT3 functions as tumour suppressor in KrasG12D/þ lung
tumours as well as KRASmutant human AC cell lines. Deletion of
STAT3 in KrasG12D/þ lung tumours and human AC resulted in
an increased tumour growth, higher tumour grade, increased
vascularization, changes in the tumour microenvironment and
significantly reduced survival. Mechanistically, we show that
genetic ablation of Stat3 in murine as well as knockdown of
STAT3 in human cells resulted in an increase of nuclear factor-
kappa B (NF-kB)-induced expression of the pro-angiogenic
chemokine ligand 1 (CXCL1; murine orthologue to the human
IL-8), thereby promoting tumour growth. Pharmacological
inhibition of CXCL1’s cognate receptor CXCR2 normalizes
tumour vascularization and microenvironment and reduces
tumour burden. Thus, STAT3 functions as tumour suppressor
by sequestering NF-kB in the cytoplasm and thereby reducing
NF-kB-dependent CXCL1 transcription.
Results
STAT3 suppresses Kras-induced lung tumorigenesis. First, we
investigated the activation status of STAT3 within murine
KrasG12D-driven lung tumours. In all, 20–30% of tumour cells
showed active STAT3 (tyrosine 705 phosphorylated STAT3)
throughout tumour development. ELISA analysis revealed
increased expression of STAT3-activating cytokines such as EGF,
OSM and IL-6 in lungs harbouring KrasG12D-driven tumours
compared with healthy control lungs (Supplementary Fig. 1a,b).
To functionally test the role of STAT3 during KrasG12D-driven
lung tumour formation, we crossed the KrasLSL-G12D/þ strain19
with conditional Stat3fl/fl mice20. Lung epithelial-specific activation
of oncogenic KrasG12D and concomitant deletion of Stat3 was
achieved by adenoviral delivery of Cre-recombinase (AdCre)
through inhalation of 8- to 10-week-old Stat3fl/fl:KrasLSL-G12D/þ
mice (Stat3DLep/DLep:KrasG12D/þ hereafter; DLep: deleted in the
lung epithelium). Efficient deletion of Stat3 in lung tumour cells was
confirmed by immunohistochemistry (IHC) of total STAT3
(Supplementary Fig. 1c). Notably, genetic ablation of Stat3
resulted in a markedly shortened survival. Although Stat3DLep/
DLep:KrasG12D/þ males showed a median survival of 118 days post
AdCre infection, the control Stat3þ /þ :KrasG12D/þ male littermates
survived 175 days (Fig. 1a). Interestingly, heterozygous loss of
STAT3 within the tumours (Stat3DLep/þ :KrasG12D/þ ) led to the
same drastic phenotype as observed in Stat3DLep/DLep:KrasG12D/þ
animals with a median survival of 108 days. Of note, female
Stat3DLep/DLep:KrasG12D/þ mice showed a less pronounced survival
disadvantage when compared with their female littermate controls
(Supplementary Fig. 1d).
We performed tumour analysis in male mice at three different
stages: 6, 10 and 13 weeks post AdCre-induction. Stat3DLep/DLep:
KrasG12D/þ mice revealed a dramatically increased tumour
burden compared with littermate controls at all time points
(Fig. 1b). Already 6 weeks after tumour induction, Stat3DLep/DLep:
KrasG12D/þ mice showed an increased number of hyperplasia
(including multifocal pneumocyte hyperplasia and adenoma) as
well as malignant in situ ACs compared with control KrasG12D/þ
animals (Fig. 1c and Supplementary Fig. 1e). At 13 weeks post
AdCre-induction, the size of ACs spreading throughout the whole
lung precluded analysis of individual tumours. Therefore, we
assessed tumour area/lung area and observed significantly
increased areas of multifocal hyperplasia and in situ ACs in
Stat3DLep/DLep:KrasG12D/þ mice compared with control animals
(Supplementary Fig. 1e). Of note, small areas of invasive ACs
were observed in both experimental groups at 13 weeks post
AdCre inhalation (Supplementary Fig. 1e). In line with these
observations, Stat3-deficient multifocal hyperplasia at 6 and 13
weeks as well as in situ ACs at 6 weeks post AdCre infection
displayed significantly enhanced cell proliferation compared with
tumours from Stat3-proficient control littermates (Supplementary
Fig. 1f), whereas the low amount of apoptosis observed in the
KrasG12D-driven lung tumours was not altered upon genetic
ablation of STAT3 (refs 21,22; Supplementary Fig. 1f). In
addition, xenograft experiments using the human AC cell line
A549, which carries a KRAS mutation in the same amino acid as
our mouse lung cancer model (G12S), showed increased tumour
growth upon STAT3 knockdown, thus confirming the observa-
tions made in the mouse model (Fig. 1d and Supplementary
Fig. 2a). Together, these data show that STAT3 suppresses
tumorigenesis of KrasG12D-driven lung tumours in mouse and
human xenograft models.
Given these results, we hypothesized that human AC with a
molecular signature similar to Stat3-deficient tumours might have
a worse prognosis. To test this idea, microarray data were used to
identify differentially expressed genes between Stat3-proficient
and Stat3-deficient tumours isolated 13 weeks post induction.
Subsequent gene set enrichment analysis (GSEA) revealed that
Stat3DLep/DLep:KrasG12D/þ tumours indeed showed significant
positive enrichment for genes associated with poor prognosis in
human AC lung cancers and, conversely, significant negative
enrichment for genes associated with good prognosis in humans
(Supplementary Fig. 1g; ref. 23).
These data show that Stat3-deficient tumours share a
transcriptional profile with advanced progression and poor
prognosis observed in human AC. In addition, the gene
expression profile of murine KrasG12D tumours devoid of STAT3
signalling significantly overlapped with human KRAS mutant
lung AC, and, conversely, murine KrasG12D tumours competent
of STAT3 signalling showed a significant enrichment for genes
usually downregulated in human KRAS mutant lung AC
(Supplementary Fig. 1h; ref. 24). This result led us to test
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whether STAT3 signalling is perturbed in human lung ACs and
we analysed four different patient cohorts. Interestingly, we found
a significant decrease in STAT3 expression levels in KRAS mutant
human tumours compared with lung tumours with wild-type
KRAS in the first cohort of smoking patients (Fig. 1e). STAT3
activation status was significantly reduced when compared with
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Figure 1 | STAT3 suppresses Kras-induced lung tumorigenesis. (a) Kaplan–Meier plot showing overall survival of male mice with the indicated genotypes
infected with AdCre (nZ10 male mice per genotype; log-rank test). (b) Representative haematoxylin and eosin stainings and quantification of tumour
area/lung area in mice at indicated time points. Data were analysed by Student’s t-test and are shown as mean±s.d., n¼ 6–10. Scale bar, 800mm.
(c) Tumour grade quantification at 6 weeks post AdCre infection in Stat3DLep/DLep:KrasG12D/þ compared with Stat3þ /þ :KrasG12D/þ mice. Data were
analysed by Student’s t-test and are shown as mean±s.e.m., nZ7 mice per genotype. (d) Human A549 lung AC cells were transducted with scrambled
shRNA (shControl) or shRNA against STAT3 (shSTAT3) and 2 106 cells were injected into male nude mice (n¼ 5 per group). Data were analysed by
two-way analysis of variance with Bonferroni correction and are shown as mean±s.e.m. (e) IHC evaluation of total STAT3 in human mucinous
adenocarcinomas with or without KRAS mutation. Intensity of staining (0/þ 1/þ 2/þ 3) was multiplied by percentage of stained tumour cells. Data are
shown as mean±s.d. nZ28 per group. (Mann–Whitney U-test, P¼0.0138) (f) STAT3 mRNA expression of lung adenocarcinoma patients harbouring
smoking history at different tumour grades is shown (n¼ 139; grade I, low metastatic potential; grade II, intermediate metastatic potential; grade III, high
metastatic potential25). (Kruskal–Wallis test with Dunn’s multiple comparison testing Po0.0001) (g) Kaplan–Meier plot showing overall survival of
lung adenocarcinoma patients with smoking history stratified by high or low STAT3 mRNA expression (lower quartile, log-rank) nZ35–104 per group.
Kaplan–Meier plot showing overall survival of the (h) TCGA cohort or the (i) Rousseaux cohort stratified by high or low STAT3 mRNA expression (log-rank
test). For all graphs: *Po0.05; **Po0.01; ***Po0.001.
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an EGFR mutant cohort (Supplementary Fig. 2b). Furthermore,
analysis of the second cohort containing 139 patients with known
smoking history showed that STAT3 expression is significantly
reduced in grade III tumours (with high metastatic potential25;
Fig. 1f, P¼o0.0001)26. Furthermore, in this patient cohort we
found that low STAT3 expression levels correlate with reduced
overall survival (Fig. 1g, P¼ 0.017)26. Of note, it is well
established that smoking is strongly associated with KRAS
mutations3. In this line, STAT3 expression levels do not stratify
AC patients without smoking history, a subgroup less prone to
harbour KRASmutations3 (Supplementary Fig. 2c). The third and
fourth cohort containing 255 and 85 lung AC patient samples,
respectively, confirmed our initial findings that STAT3 expression
levels are significantly reduced in the high-risk population
(Supplementary Fig. 2d and e)27. Furthermore, low STAT3
expression correlates with poor overall survival outcome in lung
AC patients (Fig. 1h, P¼ 0.000329; Fig. 1i, P¼ 0.002099). Thus,
these results indicate that high-grade tumours as well as lung AC
are selected for low STAT3 expression presumably to overcome
STAT3-mediated tumour suppression, which is consistent with
poor survival observed in patients with low levels of STAT3 and a
smoking history.
STAT3 alters tumour microenvironment and angiogenesis.
Detailed histopathological analysis revealed that Stat3-deficient
murine tumours were better vascularized at all investigated time
points, which was corroborated by increased CD31þ and von
Willebrand Factor staining of vessel walls (Fig. 2a). Tumour
angiogenesis is mainly driven by vascular endothelial growth
factor alpha (VEGFA) and platelet-derived growth factor alpha
(PDGFA) in response to certain stimuli derived from the tumour
cells directly or from the surrounding microenvironment28.
ELISA revealed significantly increased VEGFA levels in lungs
from Stat3DLep/DLep: KrasG12D/þ mice compared with their
littermate controls at 6 weeks, whereas at 13 weeks post AdCre
infection no difference could be observed (Fig. 2b). However, at
that later time point, Pdgfa expression was significantly elevated
in Stat3DLep/DLep:KrasG12D/þ mice, which might contribute
to enhanced tumour vascularization indirectly through the
recruitment of angiogenic stroma cells29,30 (Fig. 2c).
It has been shown that tumour cell-specific Stat3 blockade
leads to changes in the tumour microenvironment and increased
immune cell infiltration31. Qualitative IHC analysis of the tumour
microenvironment revealed that several cell types are present
within the lung tumours (NK-cells, T cells, dendritic cells,
fibroblasts and macrophages. Supplementary Fig. 3a). As
macrophages and granulocytes contribute to tumour
angiogenesis32, we performed quantitative assessment of these
cell types via flow cytometry analysis of bronchoalveolar lavage
(BAL) and observed significantly more CD11bþGr1þ
granulocytes in Stat3DLep/DLep:KrasG12D/þ lungs compared with
controls at 6 and 13 weeks post AdCre-induction (Fig. 2d).
Furthermore, infiltrating CD11bþF4/80þ macrophages were sig-
nificantly elevated within tumours of Stat3DLep/DLep:KrasG12D/þ
mice at 13 weeks post AdCre in BAL, which was confirmed by
IHC (Fig. 2d and Supplementary Fig. 3b). Further analysis of
myeloid-derived suppressor cells (MDSCs), which are known to
play an important role in suppressing the antitumour immune
response33, showed that MDSCs from Stat3-deficient mice
were more differentiated towards a monocytic phenotype
(CD11bþLy6ChighLy6Glow, M-MDSCs) than to a granulocytic
phenotype (G-MDSCs, CD11bþLy6ClowLy6Ghigh) at later stages
of tumour development (13 weeks; Fig. 2e). M-MDSCs have been
postulated to be more potent in suppressing T-cell responses33.
In line with this, we found that Stat3DLep/DLep: KrasG12D/þ
animals showed an increased CD4þ /CD8þ ratio compared with
control mice at the latest time point (13 weeks), indicating a
suppression of the cytotoxic CD8þ T cells response within the
tumours (Fig. 2f).
We further investigated tumour microenvironment and
angiogenesis within our patient cohort. Correlations between
CD31 or VEGF and P-STAT3 or STAT3 did not reveal any
significant differences between KRAS wild-type and mutant cases
(Supplementary Fig. 3c,d). Qualitative assessment of infiltrating
immune cells revealed that only 3% of tumours were infiltrated
with macrophages and we did not observe any differences
between both genotypes (Supplementary Fig. 3e). However, the
number of tumours scoring positive for infiltrating granulocytes
was higher in KRAS mutant compared with KRAS wild-type
tumours (18% within the KRAS mutant versus 10% within KRAS
wild-type cohort); in addition, less cases of KRAS mutant
tumours scored positive for lymphocyte infiltration compared
with KRAS wild-type tumours (31% within the KRAS mutant
versus 48% in KRAS wild-type cohort; Supplementary Fig. 3e).
In order to substantiate the findings of our mouse model, we
analysed the human AC xenograft samples and found that
tumours lacking STAT3 showed significantly increased numbers
of infiltrating CD11bþGr1þ and CD11bþ F4/80þ cells
(Fig. 2g) and were significantly more vascularized (Fig. 2h), thus
confirming our observations in the murine model. Together,
these results implicate that STAT3 ablation results in a
considerably different tumour microenvironment composed of
more myeloid cells, increased CD4þ /CD8þ lymphocyte ratio
and enhanced angiogenesis in our murine as well as in the human
AC xenograft models.
STAT3 regulates chemoattractive CXCL1 expression. To test
if the increased recruitment of myeloid cells is a result of
changes within the local cytokine and growth factor milieu in
Stat3DLep/DLep:KrasG12D/þ tumours, we performed ELISA of
several key cytokines, which may modulate the infiltration of
myeloid cells into tumours. IL-2, IL-12p40, IL-4 and IL-17
were not detectable and we did not find differences in IL-5,
interferon-g, IL-10, IL-1a, EGF, OSM expression between the
two genotypes (Supplementary Figs 4a and 1b). Granulocyte–
macrophage colony-stimulating factor and IL-6 expression were
upregulated in Stat3-deficient tumours only at the latest time
point (Supplementary Figs 4a and 1b). Interestingly, CXCL1 was
the only cytokine, which showed a significant increase in lungs
from Stat3DLep/DLep:KrasG12D/þ mice compared with their con-
trol littermates at all time points (Fig. 3a). Cxcl1 (murine ortho-
logue to human CXCL1 and IL-8 (ref. 34)) is a well-known and
potent chemo-attractant for macrophages and granulocytes and
can induce angiogenesis35,36. In situ hybridization not only
corroborated the increased expression of Cxcl1 in Stat3-deficient
tumours but also identified the tumour cells as the main cellular
origin of Cxcl1 as confirmed by staining for the alveolar type 2
cell-specific marker SP-C (surfactant protein C) in serial sections
(Fig. 3b and Supplementary Fig. 4b). Together, these data suggest
that STAT3 negatively regulates the angiogenic and pro-
inflammatory cytokine CXCL1 in the murine model.
Next, we analysed the patient cohorts for IL-8 expression, the
human orthologue of Cxcl1 (ref. 34). Interestingly, STAT3 and
IL-8 expression tended to inversely correlate in KRAS mutant
samples, whereas KRAS wild-type samples showed a trend
towards a positive correlation between STAT3 and IL-8
expression (Supplementary Fig. 4c). Furthermore, high IL-8
expression levels have been associated with poor prognosis in
smoking patients37, a finding which we could confirm within the
second patient cohort used in this study (Fig. 3c)26.
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Figure 2 | STAT3 alters tumour microenvironment and angiogenesis. (a) IHC analysis of von Willebrand Factor (vWF) and CD31 is shown in consecutive
sections of murine lung tumours of the indicated genotype. On right, CD31þ counts per tumour area (mm2) quantification at indicated time points.
Data were analysed by Student’s t-test and displayed as mean±s.e.m. nZ5 tumours per mouse with nZ4 mice per genotype and time point. Scale bar,
50mm. (b) ELISA of VEGFA levels in lung tumour lysates at indicated time points. Data were analysed by Student’s t-test and displayed as mean±s.d.,
nZ6 mice per genotype and time point. (c) Expression levels of Pdgfa in total lungs were measured by quantitative real-time PCR at indicated time points.
Values are presented as fold change of relative mRNA expression compared with Stat3DLep/DLep:Krasþ /þ mice. Data were analysed by one-way analysis of
variance (ANOVA) with Tukey’s multiple comparison test and are shown as mean± s.d., nZ5 animals/genotype. (d) Flow cytometric analysis of
Cd11bþGr1þ granulocytes and Cd11bþ F4/80þ macrophages in bronchoalveolar lavage (BAL) at 6 and 13 weeks post AdCre. Data were analysed by
one-way ANOVA with Tukey’s multiple comparison test and are shown as mean±s.e.m. (e) Flow cytometric analysis of myeloid-derived suppressor cell
(MDSC) subsets at 6 and 13 weeks post AdCre. Data were analysed by one-way ANOVA with Tukey’s multiple comparison test and are shown as mean±
s.e.m. (f) Ratio of CD4þ/CD8þ T-cell counts in BAL are shown. Data were analysed by Kruskal–Wallis test with Dunn’s multiple comparison testing and
are shown as mean±s.e.m. Data displayed in d–f are nZ6 mice per genotype and time point, 13-week group represents two independent experiments. (g)
Flow cytometric analysis of Cd11bþGr1þ and Cd11bþ F4/80þ cells of A549 shControl versus A549-shSTAT3 xenograft tumours. Data were analysed by
Student’s t-test and are displayed as mean±s.e.m. (nZ8 tumours;Z4 mice per group). (h) IHC analysis and representative pictures of CD31þ counts per
xenograft tumour area (mm2). Scale bar, 100mm (n¼ 8 tumours/Z4 mice). Data were analysed by Student’s t-test and are shown as mean±s.e.m. For all
graphs: *Po0.05; **Po0.01; ***Po0.001.
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Figure 3 | STAT3 regulates chemoattractive CXCL1 expression. (a) ELISA of CXCL1 levels in lung lysates and BAL at 6 and 13 weeks post AdCre.
Data were analysed by Student’s t-test and shown as mean±s.d., nZ7 mice per genotype and time point. (b) Representative in situ hybridization with
probes specific for murine Cxcl1 (AS) in lung tumours at 13 weeks post AdCre. Sense probes (S) were used as negative control and surfactant protein C
(SP-C) as lung epithelial maker. Scale bar, 100 mm. (c) Kaplan–Meier plot showing overall survival of lung adenocarcinoma patient samples harbouring
smoking history with high or low IL-8 mRNA expression (expression values of upper quartile, log-rank test) nZ35–104 per group. (d) Human A549 lung
cancer cell line (KRASG12S mutated) was stimulated with designated cytokines for indicated time points. IL-8 or CXCL1 expression was analysed via
qRT–PCR. Data were analysed by one-way ANOVA with Tukey’s multiple comparison test and shown as mean±s.d. (e) A549 cells transducted with
lentiviral vectors expressing nonspecific scrambled small hairpin (sh)RNA or shRNA against STAT3 were stimulated with indicated cytokines for 60min.
Data were analysed by one-way ANOVA with Tukey’s multiple comparison test and shown as mean±s.d. (f) Primary pneumocytes were isolated and
infected with AdCre. 120 h post infection cells were stimulated with indicated cytokines for 60min. Cxcl1 expression was analysed by qRT–PCR. Data are
shown as mean±s.e.m. (g) Murine 3T3 fibroblasts and STAT3 overexpressing 3T3 fibroblasts were stimulated as in f. Cxcl1 expression was analysed by
qRT–PCR. Data were analysed by one-way ANOVA with Tukey’s multiple comparison test and shown as mean± s.d. Values in d–g are presented as fold
change of relative mRNA expression compared with each unstimulated individual cell line. At least two independent experiments with three individual
plates per stimulation were performed. For all graphs: *Po0.05; **Po0.01; ***Po0.001.
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We next performed various cytokine stimulation experiments
in vitro to corroborate the Stat3-mediated repression of Cxcl1
observed in the murine model. First, we confirmed that the
human KRAS mutant AC cell line A549 activates STAT3 in
response to cytokines such as OSM, IL-6 and EGF found to be
expressed in our murine lung tumours in vivo (Supplementary
Figs 1b and 4d). We used tumour necrosis factor-a (TNF a) to
stimulate NF-kB induced IL-8 and CXCL1 expression in A549
cells and analysed the effect of co-stimulating STAT3 by OSM or
IL-6. As expected, TNF a stimulation induced a marked IL-8 and
CXCL1 expression, which was significantly inhibited by co-
treatment with OSM (Fig. 3d). Interestingly, OSM treatment
alone also led to a very small and transient increase of IL-8 and
CXCL1. Similar results were obtained with IL-6 co-stimulation
(Supplementary Fig. 4e). Importantly, small hairpin-mediated
knockdown of STAT3 confirmed that the observed effects on
CXCL1 and IL-8 repression were at least in part mediated by
STAT3 (Fig. 3e and Supplementary Fig. 4f).
Next, we isolated primary mouse alveolar type 2 pneumocytes
from the lungs of Stat3flox/flox:KrasLSL-G12D/þ and Stat3þ /þ :
KrasLSL-G12D/þ animals (Supplementary Fig. 4g). Complete
deletion of STAT3 was observed 120 h post AdCre infection
in vitro (Supplementary Fig. 4h). In these primary cells, TNF a
treatment again triggered Cxcl1 expression albeit less pronounced
compared with A549 cells (Fig. 3f). Importantly, Stat3-deficient
KrasG12D/þ -mutant pneumocytes expressed significantly
increased levels of Cxcl1 upon TNF a stimulation compared
with syngeneic Stat3-proficient cells. Upon co-stimulation with
OSM, Stat3-deficient pneumocytes not only failed to repress
Cxcl1 expression but even showed vastly increased Cxcl1
expression levels (Fig. 3f). Conversely, experiments using murine
3T3 fibroblasts overexpressing STAT3 (ref. 10) showed that
STAT3 is not only required but is sufficient to repress Cxcl1
expression (Fig. 3g). These results suggest that STAT3 represses
Cxcl1 expression in vivo and in vitro.
CXCL1 inhibiton reverts oncogenic effects of STAT3 ablation.
Next, we tested whether CXCL1 is responsible for the increased
tumour growth supported by vascularization and infiltration. We
used the SB225002 compound to inhibit CXCL1’s cognate
receptor CXCR2, which we found to be expressed on epithelial,
endothelial and myeloid cells within the lung tumours
(Supplementary Fig. 5a)36,38. CXCR2 antagonist treatment was
conducted in two ways: first, we treated the mice 1 week after
AdCre tumour induction (Supplementary Fig. 5b). After 5 weeks
of continuous CXCR2 blockade, we could not only observe a
marked reduction in tumour vascularization but importantly
tumour incidence and overall tumour burden were reduced,
suggesting that CXCL1 is crucial for tumour development at early
stages in Stat3DLep/DLep: KrasG12D/þ mice (Fig. 4a,b). Second, we
tried to mimic a therapeutic setting and treated tumour-bearing
mice (Supplementary Fig. 5b). After 7 weeks of treatment, we
could observe a significant reduction of vascularization and of
infiltrating F4/80þ macrophages in the tumours of Stat3DLep/DLep:
KrasG12D/þ mice (Supplementary Fig. 5c), but not in overall
tumour burden (Supplementary Fig. 5d). To further confirm
these findings in a human cell line, we performed a small hairpin-
mediated double knockdown of IL-8 and STAT3 in A549 cells
(Supplementary Fig. 5e). Indeed, enhanced tumour growth of
shSTAT3 cells was significantly reduced upon knockdown of IL-8
(Fig. 4c). Furthermore, vascularization as well as macrophage and
granulocyte infiltration was reduced in the IL-8/STAT3 double
knockdown tumours compared with STAT3 knockdown tumours
(Fig. 4d,e). Interestingly, knockdown of IL-8 alone showed an
increased tumour growth in nude mice compared with shControl
cells for unknown reasons (Fig. 4c). Taken together, these data
suggest that loss of STAT3 in the tumour cells results in increased
CXCL1/IL-8 expression triggering infiltration of myeloid cells as
well as augmented vascularization, and identifies CXCL1/IL-8 as
an essential mediator for the accelerated development and
progression of Stat3-deficient tumours.
STAT3 retains p65 in the cytoplasm to reduce NF-jB activity.
Having demonstrated the importance of STAT3-mediated
repression of CXCL1 in tumour cells in vitro and in vivo, we set
out to mechanistically interrogate this pathway further. As NF-kB
subunit p65 is an important regulator of CXCL1 expression, we
first examined the p65 activation39,40. Increased levels of activated
p65 were observed, which was mirrored by increased expression
of NFkB-p65 target genes such as Tnfa, c-Myc, Il-6 and Cxcl1 in
Stat3-deficient lungs, whereas Bcl2, Bcl2l1, Ccnd1 and Ccl5 were
comparably expressed (Figs 3a,5a,b; Supplementary Figs 1b
and 6b)41. These data demonstrate that Stat3-deficient tumours
show increased NF-kB activity.
We examined the association of NF-kB and STAT3 expression
in our patient sample archive. We found a significant positive
correlation of NF-kB and STAT3 expression in KRAS wild-type
samples. On the contrary, we found a trend towards an inverse
correlation between NF-kB and STAT3 expression in KRAS
mutant samples (Supplementary Fig. 6c).
As STAT3 has been shown to compete with NF-kB on various
promoters42,43, we further analysed the crosstalk of STAT3 and
NF-kB binding on the human CXCL1 and the mouse Cxcl1
promoter. Within the mouse Cxcl1 promoter, we found several
putative STAT3-binding sites—two of them overlapping with
putative NF-kB-binding sites and conserved in humans (hereafter
termed responsive element, RE1 and 2; Supplementary Fig. 6d).
However, electrophoretic mobility shift assays of all putative
binding sites (Supplementary Fig. 6e) as well as in vivo chromatin
immunoprecipitation experiments could not reveal strong
endogenous binding of STAT3 on RE1 or RE2 (Supplementary
Fig. 6f). We next tested the human A549 cell line focusing on the
RE2 site (Fig. 5c). Upon TNF a treatment, we could detect
efficient recruitment of p65 to the CXCL1 promoter and
co-stimulation of STAT3 signalling by OSM treatment indeed
markedly reduced p65 recruitment. However, we failed to detect
direct STAT3 binding at the CXCL1 promoter site (Fig. 5c),
indicating that STAT3 regulates p65-induced CXCL1 expression
by means other than competing for promoter-binding sites.
As STAT3 and the NF-kB subunit p65 have been reported
to interact at the protein level43–45, we next tested if STAT3 may
bind and control subcellular localization of p65. Co-
immunoprecipitation experiments in A549 cells showed that
the majority of STAT3 and NF-kB–p65 interact in the cytoplasm
under basal conditions as well as upon stimulation with OSM,
TNF a or a combination thereof (Fig. 5d). We next quantified
nuclear p65 levels normalized to poly (ADP-ribose) polymerase
family, member 1 (PARP). Upon OSM stimulation, a reduction of
nuclear p65 compared with unstimulated conditions was
observed. Increased levels of nuclear p65 were obtained upon
TNF a stimulation, which was reduced to basal levels upon co-
stimulation with OSM (Fig. 5d). To further confirm this, we
analysed the subcellular localization of p65 using
immunofluorescence imaging of STAT3-proficient A549 cells
and compared it to the STAT3 knockdown cell line (Fig. 5e).
Under basal conditions, A549-shSTAT3 cells already showed
increased levels of nuclear p65 compared with controls.
Interestingly, we observed a reduction of nuclear p65 in OSM-
stimulated A549-shSTAT3 cells compared with unstimulated
controls, indicating that additional OSM-induced effectors other
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than STAT3 are also regulating the cytoplasmic-nuclear
trafficking of p65. As expected, both cell lines showed increased
levels of nuclear p65 upon TNF a stimulation. Importantly,
co-stimulation with OSM resulted in a significant reduction of
TNF a-induced nuclear p65 accumulation in A549 scrambled
control cells but not in shSTAT3-infected cells (Fig. 5e). In
summary, our results suggest that STAT3 represses NF-kB-
dependent CXCL1 expression by sequestering NF-kB in the
cytoplasm and mechanistically delineate a novel tumour-
suppressive pathway governed by the STAT3–NF-kB–CXCL1 axis.
Discussion
Personalized treatment decisions based on the genetics of the
individual tumour will be paramount to combat malignancies in
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the near future. STAT3 has been implicated in several
malignancies5,7,13,14,46 and therefore, clinical studies are
currently evaluating the efficacy of STAT3 inhibition in various
kinds of cancer46. However, although STAT3 traditionally has
been described as an oncogene7,9, recent reports have shown that
STAT3 can also behave as a tumour suppressor in the very same
organ systems9,11,12,42. In addition, other reports validated high
STAT3 expression as a potential marker for good prognosis in
human colorectal carcinoma and breast cancer47,48. Therefore,
the idea emerged that STAT3 function is context-dependent
either with regards to the oncogenic driver mutation, cancer type
or the specific tumour microenvironment.
Specifically in lung cancer, STAT3 has been shown to function
as one of the main downstream transcription factors in EGFR
mutant ACs13 and to act as an oncogene in a chemically induced
mouse model of lung cancer49. In addition, several studies of
human lung cancer specimens have shown the activation of
STAT3 in those tumours13,14,16. These findings made STAT3 an
attractive drug target to treat NSCLC patients. We hypothesized
that lung AC patients, especially those with activating KRAS
mutations, might also benefit from STAT3 inhibition. As KRAS is
still considered as an undruggable target and is responsible for
30% of all Caucasian AC cases, we investigated whether STAT3
inhibition has a potential survival benefit in a preclinical lung
cancer mouse model and in a human cell line xenograft model.
However, our results clearly show that STAT3 behaves as a
haploinsufficient tumour suppressor during KrasG12D-induced
lung tumorigenesis. Mice lacking Stat3 signalling specifically
within KrasG12D-mutant tumour cells not only display increased
tumour initiation and tumour cell proliferation but also
accelerated malignant progression and ultimately markedly
reduced survival compared to mice with intact Stat3 signalling.
We could confirm these observations in human lung AC cell-
derived xenografts. Of note, others have shown that reducing
STAT3 activity by using STAT3 inhibitors or STAT3 decoy
oligonucleotides suppressed tumour growth in xenograft-derived
NSCLC cell lines18,50,51. However, by using a powerful short
hairpin RNA (shRNA)-mediated loss-of-function approach, we
found that STAT3 suppresses tumorigenesis in A549 cell-derived
xenografts, thus supporting our findings in the murine model.
Despite the fact that Stat3-deficient tumours had a growth
advantage, they did not progress to become more invasive than
Stat3-proficient tumours or metastatic. Tumour invasion and
metastasis are a multistage development in which, in addition to
neo-angiogenesis, malignant tumour cells have to undergo EMT,
detach from the primary tumour, migrate and pass mechanical
barriers. This is a complex process driven by multiple somatic
aberrations. Thus, most likely, Stat3-deficient tumours need
additional hits to become invasive and to metastasize.
Interestingly, the observed survival disadvantage is more
pronounced in male mice than in female mice reminiscent of
observations made in the clinic: although women have a higher
incidence rate in developing lung cancer, they have a better
survival outcome compared with men52. Further on, STAT3
already has been linked to gender-specific diseases in liver and
lung cancer53,54. Detailed analysis of this gender-specific
difference associated with STAT3 will be of high interest. One
of the main pro-inflammatory and neo-angiogenesis promoting
cytokines responsible for our observations in Stat3-deficient
tumours is Cxcl1. Cxcl1, the murine orthologue to human IL-8
and CXCL1, is known to be RAS dependent40, to directly attract
myeloid cells and to stimulate endothelial cells to promote
angiogenesis35,36. Clinically, IL-8 expression is associated with a
tendency for poor prognosis in human lung cancer37 and
expression of CXCR2 also correlates with smoking and poor
prognosis55. In agreement with this, we could confirm that IL-8
expression tends to correlate with poor survival in smoking
patients (who frequently acquire KRAS mutations) within the
publically available AC patient cohort used in this study.
Interestingly, we could also show that low STAT3 expression
has a tendency to correlate with increased IL-8 mRNA expression
in KRAS mutant patient samples.
To investigate whether CXCL1 is the central angiogenesis and
tumour-promoting factor in our model and a potential
therapeutic target, we treated the mice with SB225002, a small-
molecule antagonist of CXCR2. Treating Stat3-deficient mice at
tumour initiation resulted in a reduction of tumour growth as
well as a decrease in vascularization compared with vehicle-
treated control mice. This result corroborates that CXCL1
signalling indeed accelerates tumour growth at early stages. In
addition, we cannot rule out that CXCL1 also acts as an autocrine
tumour-promoting factor in lung cancer cells56–58. We also tried
to validate CXCL1 as a therapeutic target by blocking CXCL1
signalling in established tumours. By using this approach, we
could show that tumour vascularization and infiltration of
macrophages were reduced at the end stage of the treatment;
however, we did not observe any effect on tumour growth. This
result indicates that other effectors in Stat3-deficient tumours,
like elevated NF-kB activity and/or increased c-Myc expression,
may contribute to tumour proliferation at late stages.
Nevertheless, although late-stage Stat3-deficient tumours failed
to respond to an anti-CXCL1 monotherapy, the use of CXCL1
blockers combined with standard chemotherapy or as
maintenance therapy could be a reasonable alternative to treat
these tumours and it deserves further investigation. To
substantiate these findings, we inhibited IL-8 signalling in
STAT3 knockdown human lung AC cells. Short hairpin-
mediated IL-8/STAT3 double knockdown resulted in a
Figure 4 | CXCL1 inhibiton reverts oncogenic effects of STAT3 ablation. (a) Mice were treated with the CXCR2 antagonist SB225002 or vehicle control
starting 1 week after tumour induction and euthanized after 5 weeks (treatment 1 shown in Supplementary Fig. 5b). Tumour area/lung area was quantified
within each group and at least two sections of each lung were stained with haematoxylin and eosin and analysed in a blinded manner. Tumour grading is
shown in the right panel (n¼4–7 mice per genotype). Data in both panels were analysed by one-way ANOVA with Tukey’s multiple comparison test and
shown as mean±s.e.m. Scale bar, 2mm. (b) Tumour vascularization was quantified by CD31þ counts per tumour area (mm2). At least 3 tumours per
mouse were analysed with n¼4–7 mice per genotype and treatment. Data were analysed by one-way ANOVA with Tukey’s multiple comparison test and
shown as mean±s.e.m. Scale bar, 100mm. (c) Short hairpin-mediated knockdown of IL-8 (shIL-8) in either shControl or shSTAT3 A549 NSCLC cells
were performed and 2 106 cells were injected in both flanks of male nude mice (n¼ 5 per group). Xenograft tumour growth was determined at indicated
time points. Data were analysed by Two-way ANOVA with Bonferroni multiple comparison test and shown as mean±s.e.m. (d) IHC analysis of CD31þ
counts per tumour area (mm2) showed reduced vascularization of A549-shSTAT3;shIL-8 xenograft tumours compared with controls. Data were analysed by
one-way ANOVA with Tukey’s multiple comparison test and shown as mean±s.e.m. Scale bar, 100mm. (e) Flow cytometric analysis of Cd11bþGr1þ
granulocytes and Cd11bþ F4/80þ macrophages displayed reduced myeloid infiltration in A549-shSTAT3;shIL-8 xenograft tumours compared with controls
(nZ8 tumours; 5¼mice per group). At least 6 tumours per mouse were analysed with nZ7 mice per genotype and treatment. Data were analysed by
Kruskal–Wallis test with Dunn’s multiple comparison testing and shown as mean±s.e.m. For all graphs: *Po0.05; **Po0.01; ***Po0.001.
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reduction in tumour growth, tumour vascularization and
macrophage infiltration compared with STAT3 single
knockdown within the human A549 xenograft model. These
results confirm the central role of CXCL1/IL-8 signalling in
mutated KRAS STAT3-deficient murine and human xenograft
tumours.
Mechanistically, we show that STAT3 signalling can repress
NF-kB-driven CXCL1/IL-8 expression not only in primary mouse
pneumocytes but also in human lung AC cells. Furthermore, we
show that tumours lacking Stat3 showed increased nuclear p-p65
concomitant with increased expression of CXCL1 and other
typical NF-kB target genes, such as Tnfa, c-Myc and Il-6, which
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was also shown by others in A549 cells as well as in glioblastoma
cells upon STAT3 blockade59,60. Although STAT3 as well as other
STAT family members has been shown to compete with NF-kB
on various promoter regions43,61,62, we could not detect direct
STAT3 binding to the CXCL1 promoter. We found that
activation of STAT3 results in binding to and retention of
NF-kB in the cytoplasm, thereby reducing NF-kB transcriptional
activity. In line with these results, Stat3 deficiency in dendritic
cells63 and splenocytes as well as knockdown or inhibition of
STAT3 within melanoma or prostate cancer cell lines44 causes
increased phosphorylation of IkBa, indicating that STAT3 can
also impinge on NF-kB activity further upstream in the inhibitory
complex formation of IkBa and NF-kB.
Interestingly, mucinous lung AC patients with KRAS
mutations not only show reduced STAT3 expression levels but
also reduced STAT3 activation levels compared with smoking
patients without KRAS mutations and to EGFR mutant cases.
Further analysis revealed that more tumours with high granulo-
cyte and low lymphocyte infiltration were found within KRAS
mutant patient samples. In addition, low STAT3 expression
tends to correlate with increased NF-kB and IL-8 expression.
Nevertheless, increased patient numbers are needed to sub-
stantiate these findings. Furthermore, in lung AC patients with a
known smoking history, a patient subgroup associated with
KRAS mutations, we found a significant correlation between
lower STAT3 expression and poor survival. In line, those tumours
with advanced stage (grade III) had significantly less STAT3
expression, indicating that STAT3 downregulation seems to be
beneficial for tumour progression. Furthermore, two additional
independent data sets confirmed that STAT3 expression was
significantly downregulated in high-risk patients with subsequent
poor survival outcome in lung AC patients. GSEA further showed
that our murine Stat3-deficient KrasG12D tumours strongly
correlate with a gene expression signature associated with human
KRAS mutant lung tumours, and importantly, also with a poor
prognosis-gene signature—more than Stat3-proficient KrasG12D
tumours. These data suggest that our observations in the Stat3-
deficient KrasG12D mouse model are actually reflecting the human
situation where tumour grade and poor prognosis correlate with
low STAT3 expression in lung AC patients.
Based on in vitro studies and xenograft models, STAT3 is
considered to play a tumour-promoting role in EGFR mutant
NSCLC13,14,16,18, therefore, inhibition of STAT3 is considered as
therapeutic intervention in lung ACs46. We have demonstrated
that STAT3 has a tumour-suppressor function in murine Kras
mutant lung cancer as well as in human KRASmutant xenografts.
Although further clinical investigations will be required, our data
suggest that those lung AC patients harbouring KRAS mutations
or a known smoking history (as a surrogate marker for KRAS
mutations), may not respond to STAT3 inhibitors but may likely
suffer severe adverse effects. This highlights the importance of
stratifying patients according to their driver mutation for further
therapeutic interventions. In addition, our study also proposes a
re-evaluation of STAT3 inhibitors46 as therapeutic strategies for
any inflammatory or fibrotic disease or cancer, as inhibition of
STAT3 in vivo might bear the risk of triggering malignant
transformation of incipient pre-malignant cells harbouring KRAS
mutations within the lung.
Methods
Tumour induction and inhibitor administration in mice. Mice carrying the
Stat3floxed allele20 were crossed with the KrasLSLG12D/þ knock-in mice19 to
generate Stat3flox/flox:KrasG12D/þ mice maintained on a C57BL6/N background. In
all experiments described, littermates were used as controls. All mice were bred and
maintained according to an ethical animal licence protocol complying with the
current Austrian law. Induction of lung tumours via intranasal AdCre inhalation
was performed with 2.5 107 plaque-forming unit as described64. Stat3DLep/DLep:
KrasG12D/þ and Stat3þ /þ :KrasG12D/þ mice were treated with SB225002
(Tocris#2725) as following: 1 week or 6 weeks post Adenoviral Cre infection,
mice were injected either with vehicle or SB225002 (dissolved in PBSþ 0.25%
Tween-20) with doses of 0.5mg kg 1 bodyweight intraperitoneally 5 days per
week for 5 or 7 weeks, respectively. Treatment was performed according to an
animal licence protocol approved by the Bundesministerium fu¨r Wissenschaft
und Forschung (BMWF-66.009/0252-II/3b/2013).
Xenograft experiments. A total of 2 106 cells were mixed 1:2 with Matrigel
(Corning#356231) and injected into left and right flank of Hsd:Athymic Nude-
Foxn1nu male mice (3–4 weeks age, Harlan). Tumour volumes were evaluated
twice a week by measuring two perpendicular diameters with calipers. Tumour
volume was calculated using the following equation: (width*width*length)/2.
Treatment was performed according to an animal licence protocol approved
by the Bundesministerium fu¨r Wissenschaft und Forschung (BMWF-66.009/0280-
II/3b/2012).
Human data. A tissue microarray was produced for mucinous lung ACs. Out of
346 human lung AC cases, 74 were selected that harboured a known smoking
history and showed a mucinous differentiation. In comparison to non-mucinous
ACs, mucinous subtypes harbour a KRASmutation in 56% of cases (versus 25–30%
in non-mucinous AC), thus increasing the probability to identify a significant
amount of mutated cases (P.H., unpublished data). Human tissue samples were
analysed with prior approval by the institutional ethical committee (24–135 ex
11/12). Gene expression data and overall survival information were analysed as
described26. In brief, the GEO, EGA and TCGA repositories were searched for
suitable databases containing raw microarray and survival data as well as clinical
characteristics including smoking history for lung AC samples. Two GEO data sets
(GSE29013 and GSE31210) fulfilled these criteria. For all samples in these data sets,
normalized gene expression was recomputed using MAS5. Then, to analyse the
prognostic value of STAT3 or IL-8, the lung AC patient samples with or without
smoking history were split into two groups according to lower/upper quartile
expression of STAT3 or IL-8, respectively. The used probe set for STAT3 was
208991_at and for IL-8 it was 202859_x_at. The two patient cohorts were analysed
by Kaplan–Meier survival plot and the hazard ratio with 95% confidence intervals
and log-rank P value were calculated. The data sets used to determine the
prognostic value of STAT3 in the lung AC patients27 are taken from GSE30219
and based upon data generated by the TCGA Research Network: http://
cancergenome.nih.gov/.
Figure 5 | STAT3 retains p65 in the cytoplasm to reduce NF-jB activity. (a) NF-kB subunit p65 activation status (p-p65) was analysed by IHC.
nZ5 tumour sections per mouse per genotype and time point. Data were analysed by Student’s t-test and are shown as mean±s.d. Scale bar, 100mm.
(b) qRT–PCR of NF-kB subunit p65 target genes (Tnfa, c-Myc) from total lungs at 13 weeks post AdCre. nZ4 mice per genotype. Data were analysed by
one-way ANOVA with Tukey’s multiple comparison test and are displayed as mean±s.e.m. (c) Chromatin immunoprecipitation (ChIP) of NF-kB
subunit p65 or STAT3 binding on human CXCL1 (responsive element 2, RE2). A549 cells were stimulated with indicated cytokines for 10min. Binding of
STAT3 and p65 on ICAM1 promoter served as positive control. ACTB element was chosen as negative binding region, indicated by the horizontal line.
Values are presented as fold enrichment relative to chromatin input. Data of two independent experiments are shown. Data were analysed by
one-way ANOVA with Tukey’s multiple comparison test and shown as mean±s.e.m. (d) A549 cells were stimulated as in c. Immunoprecipitation (IP) of
nuclear and cytoplasmic fractions was performed with antibodies against p65 or STAT3 and subjected to STAT3 and p65 immunoblot analysis, respectively.
IP inputs were subjected to STAT3 and p65 (arrow indicates unspecific binding). PARP (nuclear) and TUBA1A (cytoplasmic) were used to determine
purity of input. Densitometric quantification of bands was performed (AU, arbitrary units). (e) A549 cells transducted with scrambled shRNA or
shRNA against STAT3 were stimulated as in c and stained with antibodies for NF-kB subunit p65 (FITC). nZ6 regions of interest were quantified.
White scale bar, 20mm. Data were analysed by one-way ANOVA with Tukey’s multiple comparison test and shown as mean± s.e.m. For all graphs:
*Po0.05; **Po0.01; ***Po0.001.
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Histology. For histological analysis of lung tumours, 2.5mm sections from at least
two different central planes of the lungs were cut, stained with haematoxylin and
eosin and scanned with TissueFaxs software (TissueGnostics GmbH). Quantification
of tumour area, tumour number and tumour grade was done with HistoQuest
software (TissueGnostics GmbH) and visually controlled by two independent
pathologists (R.H.Z. and H.P.) in a blind manner. Tumour grade was classified as
following: hyperplasia includes diffuse hyperplasia of pneumocytes type II and
adenomas. The first is a diffuse proliferation, whereas adenomas are circumscribed.
Adenomas can be composed of transformed pneumocytes type II but also can
contain some Clara cells. Both lesions represent non-malignant proliferations, have a
compact cell mass, alveolar septae are still intact and the nuclear/cytoplasmic ratio is
still regular. In situ ACs grow along preexisting alveolar septae, have prominent
nucleoli and an increased nuclear/cytoplasmic ratio, but still low mitotic counts per
high-power field. Sometimes this proliferation appears pseudosolid, because of
alveolar collapse or increased cell size obscuring the alveolar lumen. Into this cate-
gory we also included intrabronchiolar papillary neoplasia as the lesion from which
in situ ACs develop. Invasive ACs were classified by harbouring desmoplastic stroma
formation (confirmed by Movat pentachrome staining: elastic lamina are stained
black-brown; collagen III and V are stained green; collagen I is stained yellow; cells
are stained dark red; mucins are stained blue.), invasion into the desmoplastic stroma
or lymphatic or blood vessels and high mitotic counts per high-power field.
In situ hybridization and IHC. Digoxigenin labelled RNA fragments for Cxcl1 were
used as probes for in situ hybridization. Human in situ hybridization was performed
used the RNAscope 2.0 High Definition assay65 according to the manufacturer’s
instructions (Advanced Cell Diagnostics, Inc.) to detect human IL8 transcripts
(Probe—Hs-IL8, 310386). As positive and negative control, we used the RNAscope
Hs-POLR2A (310451) and dapB (310043) control probe sets. IHC was performed
using antibodies against P-STAT3 (Cell Signaling#9145, 1:100), ser276 p-p65 (Cell
Signaling#3037; 1:50), p65 (Santa Cruz#372, 1:200), total STAT3 (N-terminal,
BD#610189; 1:200), CD31 (Dianova#DIA-310, 1:50), SP-C (Santa Cruz#13979,
1:100) and F4/80 (AbD Serotech#MCA497G, 1:80), NKp46 (BioLegend#137602;
1:200), Cd11c (Biolegend 117301, 1:200), CD3 (Neomarkers RM9107, 1:100), FSP1
(Millipore 07–2274, 1:600) using standard protocols. At least five different high-
power field sections ( 200 objective) per mouse and per genotype were compared.
Quantification for IHC were either done with HistoQuest or for IF staining with
TissueQuest (TissueGnostics, GmbH). Image analysis parameters (cell size, cell
shape, nuclear size, nuclear shape) were used to discriminate between stroma and
tumour cells and were adjusted under the supervision of two board certified
pathologist (H.P. and R.H.Z.) to ensure that quantification of P-STAT3 staining in
tumour stroma cells versus tumour cells was properly performed.
Microarray analysis. Total RNA from four tumours/genotype at 13 weeks post
AdCre were isolated using the RNAeasy Kit (Qiagen#74104), pooled and hybri-
dized to GeneChip Mouse Gene 1.0 ST array (Affymetrix). GSEA was performed to
analyse changes in functional gene sets66. Microarray data and description of
experimental design are deposited under GEO number GSE52798.
Cytokine measurement. Cytokine Bead Array (eBioscience #BMS820FF and
#BMS86019FF) was done with the BAL of mice at 13 weeks post AdCre. In short,
lungs were instilled and flushed two times with 1ml sterile phosphate-buffered
saline each. The cytokine bead array was performed according to manual
instructions, measured with FACS Canto II (BD Biosciences) and analysed with
FlowCytomix Pro 2.4 (eBioscience). For lung lysates, a piece of frozen lung was
homogenized in phosphate-buffered saline and three freeze–thaw cycles were
performed to breakup cellular membrane. Afterwards supernatants were used and
ELISA was performed according to the manual instructions (R&D #M6000B,
#MEG00, #MKC00B, #AF495NA, #BAF495, #495MO025; eBioscience #BMS612).
For labelling of infiltrating immune cells, BAL of mice at 6 and 13 weeks post
AdCre was used. Single-cell suspensions were labelled overnight at 4 C with
appropriate antibodies in phosphate-buffered saline. The number of macrophages,
granulocytes and MDSCs are defined by the total number of cells in BAL multi-
plied by the percentage of each cell type identified by flow cytometry (FACS Canto
II (BD Biosciences)) and analysed by FlowJo (TreeStar, Inc.).
In vitro experiments and isolation of primary pneumocytes. A549 cells were
supplied from ATCC and maintained at standard conditions. STAT3a over-
expressing 3T3 cells and 3T3 control cells were provided by R.M. and described
elsewhere10. Stimulation experiments were done with human OSM (#11344022),
human IL-6 (#11340060), human TNF a (#11343013), murine IL-6 (#12340063)
and murine TNF a (#352392), all from Immunotools. Murine OSM (#495MO025)
was purchased from R&D. At least two independent experiments with three
individual plates per stimulation were performed. Isolation of primary
pneumocytes was performed as described previously22. Briefly, lungs were inflated
with 3ml Dispase II (BD#354235), digested with 0.01% DNase1 (SIGMA#D5319)
and filtered through 100, 70 and 45 mm filters. Immune cells were negatively
selected with CD16/CD32-coated dishes (BD#553142). Supernatant containing
pneumocytes was maintained with F12 (GIBCO#VX21765037) media containing
penicillin/streptomycin, 2% FBS, ITS Supplements (SIGMA#ITSI1884), 0.8mM
CaCl2, 15mM HEPES, 0.25% BSA. Purity of the batch was confirmed by
immunofluorescence staining (Santa Cruz#13979, 1:100) and nine different high-
power fields were quantified by Tissuequest. Forty-eight hours after isolation, cells
were infected with calcium precipitated adenoviral particles (University of Iowa,
Gene Transfer Vector Core) with a multiplicity of infection (MOI) of 250.
Stimulation experiments were performed 120 h post Adenoviral Cre infection.
Short hairpin-mediated knockdown. Lentivirus production and subsequent
transduction of cells was carried out as described earlier67. The following shRNA
constructs (Sigma Aldrich mission TRC library) were used: shRNA against STAT3
(TRCN0000071456) and control scrambled shRNA (SHC002). The functionality of
the shRNAs was validated by immunoblot. Transduced cells were selected for
puromycin resistance before further analysis. Within a different approach we used
two STAT3-specific shRNAs (#336, #946) and a control shRNA (#713) and cloned
them into a retroviral tetracycline-inducible expression vector68 containing the
optimized miR-E backbone69. Retroviral production and subsequent transduction
of cells were performed as described earlier68. Transduced cells were selected for
neomycin resistance and doxycycline was used to induce shRNA expression.
Cells were sorted for green fluorescent protein and dsRed prior usage. Short
hairpin-mediated knockdown of IL-8 was performed by cloning IL-8-specific
shRNA (#1255) into a lentiviral expression vector containing the optimized miR-E
backbone69. Lentiviral production, transduction and selection with neomycin were
performed as described69. Cells were sorted for green fluorescent protein in
addition to antibiotic selection prior usage.
Chromatin immunoprecipitation. Chromatin isolation was done according to
previously described protocol70. Briefly, 5 106 A549 cells were harvested and
fixed in 2mM Di-succinimidyl Glutarate (Sigma #80424) for 45min at room
temperature. After washing, fixation with 1% formaldehyde was done for 7min and
stopped with 2.5M glycine. Chromatin was washed and sonicated in lysis buffer
(20% SDS, 0.5M EDTA, 1M Tris (pH 8.1), 50 Proteinase Inhibitor Complete
(Roche#11697498001), 1,000 phenylmethylsulphonyl fluoride, 100 Na3Vo4).
Samples were sonicated for 25 cycles at 4 C; each sonication cycle was for 30 s
followed by a 30-s pause. 1% of the chromatin supernatant was kept as input.
Immunoprecipitation (IP) was performed with 100mg chromatin incubated with
1:100 diluted antibody (p65#8242, STAT3#9134 both Cell signaling, IgG
control#2027 Santa cruz) for 1 h on ice. Fifty microlitres of pre-cleared beads
(Life Technolgies#10004D) were added per IP and incubated rolling overnight at
4 C. Next day, chromatin-bead complexes as well as chromatin input were washed
with RIPA, high salt, lithium chloride and two times TE buffer before chromatin
complexes were eluted in elution buffer (10%SDS, 0.1M NaCO3, 10mM
dithiothreitol) for 30min at room temperature. Reversing the chromatin crosslink
was done with 4M NaCl at 65 C for more than 4 h. The IP complexes were
harvested overnight at 55 C by adding 0.5M EDTA, 1M Tris (pH 6.5) and
Proteinase K (10mgml 1). Chromatin-DNA was isolated with Phenol/
Chloroform/Isoamyl Alcohol mixture (Invitrogen#15593-031) according to
protocol. DNA was subjected to quantitative reverse transcription–PCR
(qRT–PCR; Kappafirst Peqlab#07KK600-03) and amount of amplification
quantified with standard curves. Primer pairs are listed in Supplementary Table 1.
RNA and real-time quantitative PCR. QRT–PCR was performed on TRIzol
(Invitrogen#15596018) or Qiagen (#74104) isolated RNA. Complementary DNA
transcription was performed either with a Fermentas (#K1632) or BioRad Kit
(#1708890). qRT–PCR was performed using SYBR Green. Values were normalized
to either murine or human ACTB mRNA expression. Primer pairs are listed in
Supplementary Table 1.
IP and immunoblotting. Protein lysates and nuclear/cytoplasmic extracts
were done according to standard methods. IP was performed overnight with
specific antibodies (STAT3 #9139, p65 #8242, Cell Signaling) and protein A
Sepharose Beads (G&E#71709000AE). Immune complexes were dissolved by
SDS–polyacrylamide gel electrophoresis and immunoblots were subjected with
respective antibodies. Densitometric quantification of immunoblots was performed
with the ImageJ software (Rasband, W.S., ImageJ, US National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997–2011.) according to the
standard procedures. Cytoplasmic contaminations in the nuclear fraction were
corrected using the respective TUBA1A signal before nuclear extract signals were
normalized to the PARP-loading control. PARP (#9532 Cell Signaling), TUBA1A
(Santa Cruz#8035) or HSC-70 (Santa Cruz#7298) were used as loading controls.
Supplementary Fig. 6g shows uncropped immunoblots from Fig. 5d.
Statistics. All values are given as means±standard error of the mean (s.e.m.) or
standard deviation (s.d.) as indicated. Comparisons between two groups were made
either by Student’s t-test or Mann–Whitney U-Test; for more than two groups’ one-
way analysis of variance (ANOVA) with Tukey’s multiple comparison test or Kruskal–
Wallis test with Dunn’s multiple comparison test was performed. Tumour growth was
analysed with two-way analysis of variance and Bonferroni multiple comparison
testing. For the Kaplan–Meier analysis a log-rank test was performed. Po0.05 was
accepted as statistically significant. For all graphs: *Po0.05; **Po0.01; ***Po0.001.
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